FDA Accepts ONS-5010 BLA Resubmission, Sets July 29 PDUFA Date for Wet AMD Treatment
OTLK has more than doubled off its 52-week low of $0.161.
Summary
Outlook Therapeutics announced the FDA has accepted its Biologics License Application (BLA) resubmission for ONS-5010/LYTENAVA™ for wet AMD, setting a Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026. This marks a critical step towards potential approval for their lead product.
Key Events · Product Development and Regulatory · OTLK
-
FDA Accepts BLA Resubmission
The FDA acknowledged receipt and formally accepted the Biologics License Application (BLA) resubmission for ONS-5010/LYTENAVA™ for wet AMD.
-
PDUFA Date Set
A Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026, has been set, indicating the target date for the FDA's decision.
-
Class 1 Review Designation
The BLA resubmission was designated as a Class 1 review, resulting in an expedited 60-day review period from the resubmission date.
-
Critical Regulatory Progress
This marks a significant advancement in the regulatory pathway for ONS-5010, a key product for a company previously flagged with "going concern" warnings.
Analysis · OTLK · Life Sciences
This filing confirms the FDA's formal acceptance of Outlook Therapeutics' resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA™ and establishes a Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026. For a company facing "going concern" warnings and significant dilution, this is a highly positive development, providing a clear and near-term timeline for a potential approval decision for its lead therapeutic candidate. The Class 1 review designation indicates an expedited 60-day review period, accelerating the process.
At the time of this filing, OTLK was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $185.8M. The 52-week trading range was $0.16 to $3.39. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.